Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
PYC Therapeutics Limited ( (AU:PYC) ) has provided an announcement.
PYC Therapeutics has made significant progress in its drug development programs during Q2 2025, including advancing clinical trials for treatments targeting polycystic kidney disease, retinitis pigmentosa type 11, and autosomal dominant optic atrophy. The company also presented pre-clinical data for a neurodevelopmental disorder treatment. Following a successful capital raise, PYC is well-positioned financially to continue its journey toward becoming a commercial-stage company, with key milestones expected in the latter half of 2025.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a biotechnology company specializing in precision medicine, focusing on developing RNA therapeutics for patients with severe unmet medical needs. The company is advancing a pipeline of four first-in-class drug candidates, with three programs having progressed into human trials.
Average Trading Volume: 533,399
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$793.2M
See more insights into PYC stock on TipRanks’ Stock Analysis page.